AUS
NZ
UK
CA
USA
IND
Healthcare
Elixinol Wellness (ASX:EXL) Shares Track All Ordinaries Index
January 19, 2026 04:11 PM AEDT| By SamThis article outlines Elixinol Wellness Limited operations, sector environment, and market context, describing wellness manufacturing activity alongside broader Australian equity references without performance direction.
Proteomics International Laboratories Healthcare Activity Within All Ordinaries Biotechnology Framework
January 19, 2026 01:01 PM AEDT| By SamProteomics International Laboratories operates within Australia’s biotechnology sector, advancing proteomics based diagnostics while maintaining representation within the All Ordinaries index.
ASX 300 Momentum Shapes Opening Tone as Polynovo Ltd Remains in Sector Focus
January 19, 2026 12:43 PM AEDT| By SamPolynovo Ltd remains central to ASX discussions as the market prepares for a steady open, with healthcare and biotechnology activity shaping early-session sentiment.
4DMedical’s Market Moment: What the Valuation Signals Now
January 19, 2026 12:01 PM AEDT| By SamThis article explores 4DMedical’s valuation narrative, technology outlook, and market expectations, highlighting why execution and adoption now define its position within Australia’s evolving healthcare landscape.
Genetic Signatures (ASX:GSS) Shares Track All Ordinaries Index
January 16, 2026 06:08 PM AEDT| By SamA factual profile of Genetic Signatures Limited outlining diagnostics activities, sector environment, and its connection to the All Ordinaries healthcare landscape.
Telix Pharmaceuticals Within ASX 100 and All Ordinaries Healthcare Space
January 16, 2026 05:23 PM AEDT| By SamTelix Pharmaceuticals operates within the Australian pharmaceuticals sector, reflecting healthcare innovation, index inclusion, and radiopharmaceutical industry engagement across the ASX landscape.
Neuren Pharmaceuticals (ASX:NEU) Shares Track All Ordinaries
January 16, 2026 04:50 PM AEDT| By SamA factual overview of Neuren Pharmaceuticals operations, sector role, and index presence, placing the company within the All Ordinaries and broader Australian healthcare landscape.
Pro Medicus (ASX:PME) Shares See Selling Pressure in ASX 50 Trading
January 16, 2026 04:41 PM AEDT| By SamAn objective overview of Pro Medicus as a healthcare imaging software provider, highlighting sector context, operations, and market dynamics linked to the ASX 50 landscape.
Zelira Advances Autism Drug Pathway With Landmark US Funding
January 16, 2026 01:08 PM AEDT| By SamZelira Therapeutics Ltd advances its autism drug program with landmark US funding, supporting clinical trials, regulatory milestones, and long-term value creation through a dedicated development structure.
Why New ASX Share Quotations Matter for Market-Focused Readers
January 16, 2026 11:59 AM AEDT| By SamA detailed look at how new ASX share quotations enhance transparency, maintain market order, and reflect disciplined capital structure management within Australia’s listed ecosystem.
Alcidion Group (ASX:ALC) Shares Rise Modestly in All Ordinaries Healthcare
January 15, 2026 07:48 PM AEDT| By SamAlcidion Group highlights descriptive revenue growth, sector-relative performance, and price-to-sales metrics within the All Ordinaries healthcare technology sector, reflecting market positioning trends.
Clinuvel Advances Pipeline as New Platform Gains Momentum
January 15, 2026 07:18 PM AEDT| By SamClinuvel Pharmaceuticals (ASX:CUV) continues to draw attention within the Australian healthcare space as it moves forward with a new controlled-release injectable platform, reinforcing its broader strategy within the ASX stock market ecosystem.
Neuren’s Daybue Momentum Draws Focus as Market Reassesses
January 15, 2026 06:45 PM AEDT| By SamNeuren Pharmaceuticals draws market attention as Daybue’s commercial progress and global expansion plans reshape expectations within the ASX biotech landscape.
Recce’s Synthetic Antibiotics Take Aim at Global Infections
January 15, 2026 05:40 PM AEDT| By SamAn in-depth look at Recce Pharmaceuticals’ synthetic anti-infective platform, global clinical progress, and relevance within the broader ASX stock market and healthcare innovation landscape.
New Board Direction Puts Mesoblast in Sharper Focus
January 15, 2026 04:50 PM AEDT| By SamMesoblast reshapes its board after a key regulatory milestone, signalling a transition from research focus toward commercial execution within the evolving Australian equity landscape.
Race Oncology update highlights healthcare activity across ASX 300 landscape
January 15, 2026 04:19 PM AEDT| By SamRace Oncology progresses a standard ordinary securities quotation application, reflecting healthcare sector activity and ongoing participation across key ASX indices.
Fresh ASX Move Puts Adheris Health Back in Market Focus
January 15, 2026 12:16 PM AEDT| By SamA routine ASX quotation update from a healthcare technology firm highlights how administrative steps support liquidity, transparency, and confidence across the Australian equity market.
DAYBUE Momentum Builds as Global Reach Expands
January 14, 2026 08:24 PM AEDT| By SamNeuren Pharmaceuticals strengthens its global footprint as DAYBUE expands through innovation, patient uptake, and international regulatory milestones, reinforcing long-term visibility in neurological care.
Imugene Advances Oncology Strategy Within ASX 300 Landscape
January 14, 2026 08:24 PM AEDT| By SamImugene confirmed a share quotation request following option conversions, reflecting standard capital structure updates within the Australian healthcare and biotechnology segment.
R&D Refund Strengthens Recce’s Innovation Momentum
January 14, 2026 05:02 PM AEDT| By SamRecce Pharmaceuticals receives a research tax incentive refund, strengthening funding for advanced anti-infective development and supporting continued progress across clinical and manufacturing initiatives.
Advertise your brand on Kalkine Media